Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival-Reference-Cited by-同舟云学术

Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival

Published:2021-12 Issue:12 Volume:39 Page:837.e9-837.e17
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Pieretti Alberto C.^ORCID,Shapiro Daniel D.,Westerman Mary E.^ORCID,Hwang Hyunsoo^ORCID,Wang Xuemei,Segarra Luis A.,Campbell Matthew T.,Tannir Nizar M.,Jonasch Eric,Matin Surena F.^ORCID,Wood Christopher G.,Karam Jose A.^ORCID

Funder

University of Texas MD Anderson Cancer Center

National Institutes of Health

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Renal cancer;Capitanio;Lancet,2016

3. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

4. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma;Méjean;N Engl J Med,2018

5. Contemporary cytoreductive nephrectomy provides survival benefit in clear-cell metastatic renal cell carcinoma;Palumbo;Clin Genitourin Cancer,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens;World Journal of Urology;2024-07-24

2. Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring;Cancers;2023-10-11

3. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy;European Urology Focus;2023-09

4. The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma;Cancers;2023-07-29

5. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma;Medicina;2022-02-23